NASDAQ · IRIXHealthcareElectromedical Equipment

Iridex financials

$0.6350+2.40%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Jan 3
FY24
Dec 28
FY23
Dec 30
FY22
Dec 31
FY21
Jan 1
FY20
Jan 2
FY19
Dec 28
FY18
Dec 29
FY17
Dec 30
FY16
Dec 31
Revenue$52.7M$48.7M$51.9M$57.0M$53.9M$36.3M$43.4M$42.6M$41.6M$46.2M
Gross profit$19.2M$19.5M$21.8M$25.4M$22.8M$15.6M$17.9M$17.5M$15.5M$20.8M
Gross margin36.5%40.1%42.0%44.5%42.4%42.8%41.3%41.0%37.3%45.1%
Operating income-$2.6M-$8.3M-$10.0M-$7.5M-$7.5M-$6.6M-$9.0M-$12.9M-$13.1M-$2.6M
Net income-$4.4M-$8.9M-$9.6M-$7.5M-$5.2M-$6.3M-$8.8M-$12.8M-$12.9M-$11.7M
Net margin−8.4%−18.3%−18.5%−13.2%−9.7%−17.4%−20.3%−30.1%−30.9%−25.4%
Diluted EPS$-0.26$-0.54$-0.59$-0.47$-0.34$-0.46$-0.64$-1.05$-1.11$-1.15
EBITDA-$2.0M-$7.7M-$8.9M-$7.1M-$5.8M-$6.1M-$8.3M-$12.1M-$12.2M-$1.8M
Operating cash flow-$2.1M-$7.3M-$6.7M-$9.5M$8.2M-$3.2M-$7.9M-$10.0M-$3.6M-$144.0K
Free cash flow-$2.3M-$7.3M-$6.9M-$9.8M$8.0M-$3.3M-$8.0M-$10.5M-$4.1M-$1.2M
Diluted shares16.9M16.4M16.1M15.9M15.4M13.8M13.7M12.2M11.6M10.2M

Balance sheet

Period endJan 3Dec 28Dec 30Dec 31Jan 1Jan 2
Cash & equivalents$6.0M$2.4M$7.0M$13.9M$23.9M$11.6M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$3.7M$2.7M$0.00$0.00$0.00$2.5M
Total assets$29.2M$29.1M$34.4M$42.3M$48.7M$28.0M
Total liabilities$24.2M$27.0M$24.9M$25.1M$25.4M$10.6M
Shareholders' equity$4.9M$2.1M$9.5M$17.2M$23.3M$17.4M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology